Treatment outcomes of isoniazid-resistant (Rifampicin susceptible) tuberculosis patients in Uzbekistan, 2017–2018
Sayfutdinov Z. Kumar A. Nabirova D. Gadoev J. Turaev L. Sultanov S. Alaverdyan S. Parpieva N.
2 March 2021MDPI AG
International Journal of Environmental Research and Public Health
2021#18Issue 61 - 8 pp.
Tuberculosis patients “resistant to isoniazid and susceptible to rifampicin (Hr-TB)” remain neglected, despite a high burden and poor outcomes. The World Health Organization (WHO) recommends a 6 month regimen consisting of levofloxacin, rifampicin, ethambutol, and pyrazinamide (LRZE) to treat Hr-TB. In contrast, Uzbekistan uses a 9 month regimen (LRZE plus a second-line injectable in the first 3 months). We aimed to assess the treatment outcomes of this novel regimen among Hr-TB patients treated in two regions of Uzbekistan (Fergana and Bukhara) in 2017–2018. We conducted a cohort study involving secondary analysis of routine surveillance data. Of 132 Hr-TB patients, 105 (80%) were successfully treated. Death was the predominant unsuccessful outcome (13, 10%) followed by “treatment failure” (10, 8%) and “lost to follow-up” (4, 2%). High treatment success is an indicator of the potential effectiveness of the novel regimen and adds to the limited global evidence on this issue. However, the sample size was small and there was no comparison group. Since the study was conducted in two regions of Uzbekistan only, the findings have limited generalizability. We recommend future research using an adequate sample size and an appropriate study design (randomized controlled trial or prospective cohort with a control group receiving the WHO-recommended regimen).
Central Asia , Hr-TB , Isoniazid resistance , Mono resistance , Operational research , SORT IT (Structured Operational Research Training Initiative) , Treatment outcome
Text of the article Перейти на текст статьи
National Reference Laboratory, Tashkent, 100086, Uzbekistan
International Union Against Tuberculosis and Lung Disease, South-East Asia Office, New Delhi, 110016, India
International Union Against Tuberculosis and Lung Disease, Paris, 75006, France
Yenepoya Medical College, Yenepoya (Deemed to be University), Mangaluru, 575018, India
United States Centers for Disease Control and Prevention, Central Asia Region, Almaty, A25T0A1, Kazakhstan
WHO Country Office in Uzbekistan, Tashkent, 700029, Uzbekistan
Bielefeld Graduate School of Economics and Management (BiGSEM), Bielefeld University, Universitätsstraße, Bielefeld, 33615, Germany
National Tuberculosis Programme, Ministry of Health, Tashkent, 100086, Uzbekistan
National Reference Laboratory
International Union Against Tuberculosis and Lung Disease
International Union Against Tuberculosis and Lung Disease
Yenepoya Medical College
United States Centers for Disease Control and Prevention
WHO Country Office in Uzbekistan
Bielefeld Graduate School of Economics and Management (BiGSEM)
National Tuberculosis Programme
10 лет помогаем публиковать статьи Международный издатель
Книга Публикация научной статьи Волощук 2026 Book Publication of a scientific article 2026